They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Gardasil, which prevents cancers caused by the human papillomavirus (HPV), has been ... compared with analyst forecasts of around $7.4 billion. Total revenue rose to $15.6 billion from $14.6 ...

Why it matters: HPV vaccine Gardasil has been hit by economic weakness ... We anticipate peak sales for pulmonary hypertension drug Winrevair around $4 billion, and we're bullish on the mRNA ...

Gardasil, which prevents cancers caused by the human papillomavirus (HPV), has been ... compared with analyst forecasts of around $7.4 billion. Total revenue rose to $15.6 billion from $14.6 ...

Gardasil is a vaccine that prevents cancer from HPV, the most common sexually transmitted ... posted nearly $1.4 billion in sales, up 9% from the same period a year ago. The company said higher ...